Quris

Quris is a biotechnology company that uses AI to predict whether a drug candidate will be safe and effective in humans before it reaches clinical trials. Roughly 89% of drug candidates fail in human trials despite passing earlier animal and lab testing, and Quris was built to close that prediction gap by generating better data earlier in the development process. Its core technology, called "Patients-on-a-Chip," miniaturizes human tissue using stem cells engineered to mimic different organs, connected on a chip so researchers can observe how a drug and its metabolites behave across a simulated body. Nanosensors monitor the cellular response, and that data trains machine-learning classification algorithms that predict clinical outcomes — an approach the company positions as more human-relevant than traditional animal testing, particularly for rare genetic diseases that can't be modeled in animals. Quris is based in Boston and Tel Aviv, was founded in 2019, and counts Nobel laureate Aaron Ciechanover and Moderna co-founder Robert Langer among its scientific leadership. The company has partnered with Merck KGaA and raised institutional seed funding. Quris serves pharmaceutical companies rather than individual users, and because its platform is a research and development service rather than a self-serve software product, pricing and direct access details are not published on its site.